A wide range of advanced monitoring assays is currently used to determine phenotypical and functional characteristics of antitumor T-cells in cancer immunotherapy trials, including T-cell proliferation, cytokine profile, CTL assays, CTL-associated molecules (CD107, perforin, granzyme B, and CD154), and MHC-multimer analysis. This evidence concerns the gene PRF1 and cancer.